

FDA-DS-T04
Subject Disposition
All Subjects

	Xanomeline Low Dose (N=XX) n (%)	Xanomeline High Dose (N=XX) n (%)	Placebo (N=XX) n (%)	Risk Difference (%) (95% CI) [1]	Risk Difference (%) (95% CI) [2]
Subjects randomized	XX (XX.X)	XX (XX.X)	XX (XX.X)		
ITT population [3]	XX (XX.X)	XX (XX.X)	XX (XX.X)		
Safety population [4]	XX (XX.X)	XX (XX.X)	XX (XX.X)		
Per-protocol population [5]	XX (XX.X)	XX (XX.X)	XX (XX.X)		
Discontinued study drug [6]	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Adverse Event	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Lack of Efficacy	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Protocol Deviation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Death	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Withdrawal by Subject	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Other	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Discontinued study [6]	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Adverse Event	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Death	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Lost to Follow-up	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Withdrawal by Subject	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Physician Decision	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Protocol Deviation	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)
Other	XX (XX.X)	XX (XX.X)	XX (XX.X)	XX.X (XX.X, XX.X)	XX.X (XX.X, XX.X)

Abbreviations: CI, confidence interval; ITT, intention-to-treat; N, number of subjects in treatment arm; n, number of subjects in specified population or group.

[1] Difference is shown between Xanomeline Low Dose vs. Placebo.

[2] Difference is shown between Xanomeline High Dose vs. Placebo.

[3] ITT population include all subjects randomized to a treatment arm.

[4] Safety population include all subjects who received at least one dose of the study drug.

[5] Per-protocol population include only those subjects who completed the treatment originally allocated and planned without major protocol violations.

[6] Percentages are based on Safety population.